PTAC Pilot and Feasibility Award
Forecasted
The PTAC Pilot and Feasibility Award supports investigators testing new basic-science ideas to restore CFTR function or repair or replace the defective gene, with the goal of advancing cystic fibrosis therapies.
Browse similar grants
Funder: Cystic Fibrosis Foundation
Due Dates (Anticipated): May 2027 (Full application)
Funding Amounts: Up to $50,000 per year, plus up to 12% indirect costs, for up to two years
Summary: Supports pilot basic-science studies that could advance therapies to restore CFTR function or repair or replace the defective CFTR gene.
Key Information: Applicants must be independent investigators; projects continuing or extending previous work belong in the Path to a Cure Research Grant program.
Description
The Cystic Fibrosis Foundation offers this award through its Path to a Cure academic programs. It supports investigators testing new hypotheses or methods that could contribute to a cure for cystic fibrosis, including high-risk, high-reward studies. The goal is to help investigators generate enough data to compete for subsequent funding.
The program focuses on foundational strategies, tools, and technologies that could restore CFTR protein function or repair or replace the defective CFTR gene, particularly for people whose genotypes do not respond to modulators. Priorities include airway cell populations, nonsense-mutation readthrough, gene insertion, targeted delivery of genetic therapies, immune responses, and preclinical tests of efficacy and safety.
